Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study★★.

Miller AE, Vermersch P, Kappos L, Comi G, Freedman MS, Oh J, de Seze J, Truffinet P, Benamor M, Purvis A, Wolinsky JS; TOPIC study group.

Mult Scler Relat Disord. 2019 Aug;33:131-138. doi: 10.1016/j.msard.2019.05.014. Epub 2019 May 24.

2.

Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials.

Comi G, Miller AE, Benamor M, Truffinet P, Poole EM, Freedman MS.

Mult Scler. 2019 Jun 7:1352458519851981. doi: 10.1177/1352458519851981. [Epub ahead of print]

PMID:
31172849
3.

Teriflunomide real-world evidence: Global differences in the phase 4 Teri-PRO study.

Coyle PK, Khatri B, Edwards KR, Meca-Lallana JE, Cavalier S, Rufi P, Benamor M, Poole EM, Robinson M, Gold R.

Mult Scler Relat Disord. 2019 Jun;31:157-164. doi: 10.1016/j.msard.2019.03.022. Epub 2019 Mar 30.

4.

Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience.

Vukusic S, Coyle PK, Jurgensen S, Truffinet P, Benamor M, Afsar S, Purvis A, Poole EM, Chambers C.

Mult Scler. 2019 Apr 10:1352458519843055. doi: 10.1177/1352458519843055. [Epub ahead of print]

PMID:
30968734
5.

Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study.

Miller AE, Xu X, Macdonell R, Vucic S, Truffinet P, Benamor M, Thangavelu K, Freedman MS.

J Clin Neurosci. 2019 Jan;59:229-231. doi: 10.1016/j.jocn.2018.09.012. Epub 2018 Oct 20.

6.

Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.

Coyle PK, Khatri B, Edwards KR, Meca-Lallana JE, Cavalier S, Rufi P, Benamor M, Thangavelu K, Robinson M, Gold R; Teri-PRO Trial Group.

Mult Scler Relat Disord. 2018 Nov;26:211-218. doi: 10.1016/j.msard.2018.09.017. Epub 2018 Sep 15.

7.

Extraction Kinetics of As(V) by Aliquat-336 Using Asymmetric PVDF Hollow-Fiber Membrane Contactors.

Bey S, Semghouni H, Criscuoli A, Benamor M, Drioli E, Figoli A.

Membranes (Basel). 2018 Aug 2;8(3). pii: E53. doi: 10.3390/membranes8030053.

8.

Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study.

Coyle PK, Khatri B, Edwards KR, Meca-Lallana JE, Cavalier S, Rufi P, Benamor M, Brette S, Robinson M, Gold R; Teri-PRO Trial Group.

Mult Scler Relat Disord. 2017 Oct;17:107-115. doi: 10.1016/j.msard.2017.07.006. Epub 2017 Jul 6.

9.

The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies.

Freedman MS, Wolinsky JS, Comi G, Kappos L, Olsson TP, Miller AE, Thangavelu K, Benamor M, Truffinet P, O'Connor PW; TEMSO and TOWER Study Groups.

Mult Scler. 2018 Apr;24(4):535-539. doi: 10.1177/1352458517695468. Epub 2017 Mar 17.

10.

Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.

O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, Lebrun-Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas.

Neurology. 2016 Mar 8;86(10):920-30. doi: 10.1212/WNL.0000000000002441. Epub 2016 Feb 10. Erratum in: Neurology. 2016 Oct 4;87(14 ):1524.

11.

Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.

Comi G, Freedman MS, Kappos L, Olsson TP, Miller AE, Wolinsky JS, O'Connor PW, Benamor M, Dukovic D, Truffinet P, Leist TP.

Mult Scler Relat Disord. 2016 Jan;5:97-104. doi: 10.1016/j.msard.2015.11.006. Epub 2015 Nov 10.

12.

A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis.

Freedman MS, Wolinsky JS, Truffinet P, Comi G, Kappos L, Miller AE, Olsson TP, Benamor M, Chambers S, O'Connor PW.

Mult Scler J Exp Transl Clin. 2015 Dec 7;1:2055217315618687. doi: 10.1177/2055217315618687. eCollection 2015 Jan-Dec.

13.

Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis.

Kieseier BC, Benamor M.

Neurol Ther. 2014 Nov 20;3(2):133-8. doi: 10.1007/s40120-014-0020-y. eCollection 2014 Dec.

14.

Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens.

Bar-Or A, Wiendl H, Miller B, Benamor M, Truffinet P, Church M, Menguy-Vacheron F.

Neurol Neuroimmunol Neuroinflamm. 2015 Feb 12;2(2):e70. doi: 10.1212/NXI.0000000000000070. eCollection 2015 Apr.

15.

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.

Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, Bauer D, Benamor M, Truffinet P, O'Connor PW; TOPIC Study Group.

Lancet Neurol. 2014 Oct;13(10):977-86. doi: 10.1016/S1474-4422(14)70191-7. Epub 2014 Sep 2.

PMID:
25192851
16.

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.

Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, Olsson TP, Benamor M, Bauer D, Truffinet P, Church M, Miller AE, Wolinsky JS, Freedman MS, O'Connor P; TENERE Trial Group.

Mult Scler. 2014 May;20(6):705-16. doi: 10.1177/1352458513507821. Epub 2013 Oct 14.

PMID:
24126064
17.

Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis.

Bar-Or A, Freedman MS, Kremenchutzky M, Menguy-Vacheron F, Bauer D, Jodl S, Truffinet P, Benamor M, Chambers S, O'Connor PW.

Neurology. 2013 Aug 6;81(6):552-8. doi: 10.1212/WNL.0b013e31829e6fbf. Epub 2013 Jul 12.

18.

Value of 18FDG PET scan in staging of ocular adnexal lymphomas: a large single-center experience.

Zanni M, Moulin-Romsee G, Servois V, Validire P, Bénamor M, Plancher C, Rouic LL, Dendale R, Vincent-Salomon A, Asselain B, Sahli R, Decaudin D.

Hematology. 2012 Mar;17(2):76-84. doi: 10.1179/102453312X13221316477813.

PMID:
22664045
19.

(18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging.

Moulin-Romsee G, Hindié E, Cuenca X, Brice P, Decaudin D, Bénamor M, Brière J, Anitei M, Filmont JE, Sibon D, de Kerviler E, Moretti JL.

Eur J Nucl Med Mol Imaging. 2010 Jun;37(6):1095-105. doi: 10.1007/s00259-009-1377-5. Epub 2010 Mar 4.

PMID:
20204358
20.

Expression of WISP3 and RhoC genes at mRNA and protein levels in inflammatory and noninflammatory breast cancer in Tunisian patients.

Marrakchi R, Khadimallah I, Ouerhani S, Gamoudi A, Khomsi F, Bouzaine H, Benamor M, Bougatef K, Mnif S, Zitoun R, Benna F, Boussen H, Rahal K, Elgaaied AB.

Cancer Invest. 2010 May;28(4):399-407. doi: 10.3109/07357900903405926.

PMID:
20014943
21.

[Tumors of the oropharynx and oral cavity: MR, CT, PET-CT imaging].

Ala Eddine C, Piekarski JD, Benamor M.

J Radiol. 2008 Jul-Aug;89(7-8 Pt 2):968-83. French.

PMID:
18772775
22.

Simultaneous determination of Fe(III) and Al(III) by first-derivative spectrophotometry and partial least-squares (PLS-2) method - application to post-haemodialysis fluids.

Aguerssif N, Benamor M, Kachbi M, Draa MT.

J Trace Elem Med Biol. 2008;22(3):175-82. doi: 10.1016/j.jtemb.2007.12.004. Epub 2008 May 5.

PMID:
18755392
23.

Desmoplastic neurotropic melanoma in a patient with trigeminal neuralgia: FDG PET/CT and MRI.

Moulin-Romsee G, Benamor M, Neuenschwander S.

Clin Nucl Med. 2008 May;33(5):353-5. doi: 10.1097/RLU.0b013e31816a788b.

PMID:
18431156
24.

PET/CT imaging: what radiologists need to know.

Benamor M, Ollivier L, Brisse H, Moulin-Romsee G, Servois V, Neuenschwander S.

Cancer Imaging. 2007 Oct 1;7 Spec No A:S95-9. Review.

25.

Simultaneous determination of calcium and magnesium by derivative spectrophotometry in pharmaceutical products.

Benamor M, Aguerssif N.

Spectrochim Acta A Mol Biomol Spectrosc. 2008 Feb;69(2):676-81. Epub 2007 May 13.

PMID:
17590390
26.

Communication between radiologists and nuclear medicine physicians.

Benamor M, Ollivier L.

Cancer Imaging. 2007 Jun 6;7:117-8. No abstract available.

27.

[The lymphatic drainage of the mammary gland: sentinel lymph node identification seen in the light of historical anatomists].

Salmon RJ, Montemagno S, Laki F, Alran S, Charitansky H, Fourchotte V, Benamor M.

J Chir (Paris). 2007 Jan-Feb;144(1):72-4. French. No abstract available.

PMID:
17369767
28.

Validation and limitations of use of a breast cancer nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsy.

Alran S, De Rycke Y, Fourchotte V, Charitansky H, Laki F, Falcou MC, Benamor M, Freneaux P, Salmon RJ; Institut Curie Breast Cancer Study Group, Sigal-Zafrani B.

Ann Surg Oncol. 2007 Aug;14(8):2195-201. Epub 2007 Feb 9.

PMID:
17294071
29.

[Routine sentinel node detection in breast cancer. Experience of the Curie Institute].

Delahaye S, Benamor M, Nos C, Vincent-Salomon A, El Khoury C, Doridot V, Sigal-Zafrani B, Clough KB; Groupe Sein de l'Institut Curie.

Bull Cancer. 2004 Jul-Aug;91(7-8):641-7. French.

30.

[Breast cancer: atlas].

Thibault F, Benamor M, Tardivon A.

Rev Prat. 2004 Apr 30;54(8):837-8, 840. French. No abstract available.

PMID:
15274454
31.

Impact of internal mammary sentinel node imaging in breast cancer.

Benamor M, Nos C, Fréneaux P, Clough KB.

Clin Nucl Med. 2003 May;28(5):375-8.

PMID:
12702932
32.

Spectrophotometric determination of cetylpyridinium chloride in pharmaceutical products.

Benamor M, Aguersif N, Draa MT.

J Pharm Biomed Anal. 2001 Aug;26(1):151-4.

PMID:
11451652
33.
34.

Radionuclide cisternography in spontaneous intracranial hypotension.

Benamor M, Tainturier C, Graveleau P, Pierot L.

Clin Nucl Med. 1998 Mar;23(3):150-1.

PMID:
9509927
35.

Ioversol clinical safety summary.

Benamor M, Aten EM, McElvany KD, Lankin DG, James MA, Buy-Gandal T, Harashe LT, Weinandt WJ.

Invest Radiol. 1989 Jun;24 Suppl 1:S67-72.

PMID:
2687200
36.

Arteriovenous separation of the prepontine vessels as a sign of intrapontine tumour.

Wackenheim A, BenAmor M.

Neuroradiology. 1971 Dec;3(2):77-9. No abstract available.

PMID:
5164266

Supplemental Content

Loading ...
Support Center